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BACKGROUND: MicroRNAs are tiny non-coding small endogenous RNAs that regulate gene expression by translational repression,
mRNA cleavage and mRNA inhibition. The aim of this study was to investigate the hypermethylation of miR-34b/c and miR-148a in
colorectal cancer, and correlate this data to clinicopathological features. We also aimed to evaluate the hypermethylation of miR-34b/c
in faeces specimens as a novel non-invasive faecal-DNA-based screening marker.
METHODS: The 5-aza-20-deoxycytidine treatment and methylation-specific PCR were carried out to detect the hypermethylation of
miR-34b/c and miR-148a.
RESULTS: The miR-34b/c hypermethylation was found in 97.5% (79 out of 82) of primary colorectal tumours, P¼0.0110. In 75%
(21 out of 28) of faecal specimens we found a hypermethylation of miR-34b/c while only in 16% (2 out of 12) of high-grade dysplasia.
In addition, miR-148a was found to be hypermethylated in 65% (51 out of 78) of colorectal tumour tissues with no significant
correlation to clinicopathological features. However, a trend with female gender and advanced age was found, P¼0.083. We also
observed a trend to lower survival rate in patients with miR-148a hypermethylation with 10-year survival probability: 48 vs 65%,
P¼0.561.
CONCLUSIONS: These findings show that aberrant hypermethylation of miR-34b/c could be an ideal class of early screening marker,
whereas miR-148a could serve as a disease progression follow-up marker.
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MicroRNAs (miRNAs) are a class of small regulatory non-coding
RNAs of B22 nucleotides in length that modulate specific cellular
activity post transcriptionally. The miRNAs target the post-
translation level of mRNA through a sequence-specific compli-
mentary at the 30 UTR region of a gene, thus inhibiting gene
expression (Lee et al, 1993; Wienholds et al, 2005). The human
genome is encoded by at least 3% miRNAs, and up to 30% of
human protein encoding genes may be regulated by miRNA
modulation (Sassen et al, 2008). The miRNAs are shown to have
key roles in normal development and also in differentiation, cell
proliferation and apoptosis of cancer cells (Bartel, 2004; He et al,
2005). In the miRBase, thousands of miRNA have been bioinfor-
matically predicted for both prokaryote and eukaryote, and
awaiting experimental validation. Each of these miRNA could
potentially regulate up to several hundred genes at mRNA post-
translation level (Krek et al, 2005).
Previous study has shown that more than 50% of the miRNA
genes are located in cancer-associated genomic regions or in
fragile sites which are hot spots for gene deletion, amplification
and mutations (Calin et al, 2004), suggesting major functions for
miRNAs in cancer cell biology. Furthermore, miRNAs also have
been shown to be involved in a wide variety of human cancers,
including colon, pancreatic, breast, prostate, liver and ovarian
cancer, suggesting a more negative regulation of cancer cell growth
by miRNAs modulation (Michael et al, 2003; Gramantieri et al,
2007; Hurteau et al, 2007; Lee et al, 2007; Shi et al, 2007; Barbarotto
et al, 2008; Felicetti et al, 2008; Mitomo et al, 2008). Initially, miR-15
and miR-16 were shown to be involved in the pathogenesis of
chronic lymphocytic leukaemia (Calin et al, 2002), and later He et al
(2005) and Johnson et al (2005) described a relationship between a
miRNA cluster of mir-17–92 with Myc oncogenic pathway.
One of the processes that tightly link miRNAs and cancer is the
process called epigenetic modification. This epigenetic alteration
in cancer has been shown to occur together with the genetic
alterations in colorectal cancer (CRC). Thus, the aberrant
hypermethylation process drives the initiation and the progression
of colorectal polyps towards invasive of advanced stage colorectal
tumours. Two recent studies have addressed the involvement of
epigenetically silenced miRNA genes in CRC tumourigenesis
including miR-34b/c and miR-342. Moreover, miR-148a has also
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srecently been discovered to be involved in metastasis progression
in several cancers including in CRC. Therefore, the understanding
of the early process of miRNAs methylation signature in CRC is of
utmost important to define the actual tumourigenesis process
involved, other than that of hypermethylation protein coding
tumour suppressor genes (Grady et al, 2008; Toyota et al, 2008).
Analysing the promoter methylation of cancer-related genes has
been always difficult, as it involved multiple steps for the
conversion of unmethylated cytosine residues to uracil, but leaves
5-methylcytosine residues unaffected, particularly when analysing
the samples derived from tumour specimens and bodily fluids. In
this paper, we have applied the whole bisulfitome amplification
method based on isothermal multiple displacement amplification
technology. A uniquely processive DNA polymerase with a 30–50
exonuclease proofreading activity maintains high fidelity during
the replication process. This technique was developed using
REPLI-g technology to allow reproducible and representative
amplification of bisulfite converted DNA, while maintaining the
converted sequence representation (for further details can access
from http://www.qiagen.com/).
In this study, we investigate miR-34b/c and miR-148a hyper-
methylation pattern in CRC tissues and correlate it with
clinicopathological features. Furthermore, we wanted to confirm
whether miR-34b/c could be used as a possible screening marker
for the detection of malignant colonocytes in faeces as a novel non-
invasive method. We also aimed to determine the suitability of
miR-148a as a prognosis factor for CRC. We showed that miR-34b/c
could be an ideal candidate target for CRC screening in faecal
microenvironment, whereas the involvement of epigenetic
silencing factor in miR-148a correlates to poor prognosis.
MATERIALS AND METHODS
CRC cell lines and drug treatment
The CRC cell lines used in this study were HCT116, HT29, LoVo and
HCT15. All cell lines were tested for mycoplasma infection and were
grown in monolayer cultures in DMEM (HCT116, HT29), RPMI 1640
(HCT15) and Ham’s Nutrients mix F12 (LoVo) supplemented with
10–20% FBS and 1% penicillin streptomycin according to UKCCCR
guidelines (Masters et al, 2000) and as previously reported
(Kalimutho et al, 2010a). No antibiotics were added to the medium
before the treatment. The cells were trypsinised and passed twice a
week and the experiments were conducted at early passages. Later the
cells were treated with 5-aza-20-deoxycytidine (AZA; Sigma-Aldrich,
St Louis, MO, USA) for 5 days.
Quantitative PCR (qPCR)
RNA isolation, cDNA synthesis and RT–qPCR Total RNA was
isolated using miRNeasy kit according to the manufacturer’s
guideline (Qiagen, GmbH, Hilden, Germany). The integrity of total
RNA was determined by 1% agarose gel electrophoresis. Applied
Biosystems RT–qPCR primer sets for miRNA-specific reverse
transcription (Ambion Inc., TX, USA) including RNU19 and
RNU6B was used according to the manufacturer’s protocol. Briefly,
the reaction master mix containing 5 RT Buffer, 5 RT Primer,
Array-Script Enzyme Mix (Applied Biosystems, Foster City, CA,
USA) and nuclease-free water was mixed with 50ng of input
miRNA. The mixture was incubated for 30min at 371C and then
for 10min at 951C. The qPCR was carried out using the Stratagene
Real-Time PCR System (Stratagene, Agilent Technologies, Santa
Clara, CA, USA) with Applied Biosystems qRT–PCR miRNA
Detection Kit (Ambion Inc.). The PCR master mix containing
Applied Biosystems 2 PCR Buffer (with FAM labelled Taqman
probe), 1ml FAM-labeled-specific primers and cDNA from process
miRNA (Applied Biosystems). The RT products was processed as
follows: 951C for 10min, and then for 951C for 15s and 601C for
30s for up to 40 cycles (n¼2). Fold changed expression following
AZA treatment was calculated via a 2^ DDCq method.
Tissues and faecal DNA
The CRC with matched normal tissue samples were obtained from
Surgery Unit of Tor Vergata University Hospital and from
University of Siena, which were approved by both internal review
boards. A total of 81 primary CRC tissues together with 42
matched control fresh frozen tissues were used for DNA extraction.
Faecal DNA was extracted from 28 CRC patients, 39 healthy
individuals and 12 patients with high-grade dysplasia (HGD) of
colorectum.
Isolation of miRNA and DNA from CRC and normal tissue
samples
Approximately 10–15mg of fresh frozen tissues of CRC and
normal surrounding tissues were used to extract DNA using
DNAeasy kit following the manufacturer’s guideline (Qiagen).
Bisulfite conversion of genomic DNA and
methylation-specific PCR (MSP)
Bisulfite conversion of genomic DNA was performed as described
in Epitech Bisulphite Conversion kit (Qiagen) to create a template
for MSP. Briefly, 1.5mg of genomic DNA from each sample in a
volume of 20ml was mixed with an appropriate chemical solvent
provided then processed accordingly. Finally, the converted DNA
was re-suspended in 40ml distiled water to a final concentration of
25–30ngml
 1. Bisulfite-treated DNA was then used as template for
MSP, which was performed following the methylation-specific
primer (Table 1). Briefly, 2ml of bisulfite-converted genomic DNA
served as the PCR template. The 1  PCR buffer supplemented
with 1.5mM MgCl2, 0.25mM of each primer, 0.2mM of dNTPs,
0.1mgml
 1 BSA and 0.25U of Hot Start Taq polymerase (Applied
Biosystems) in a total volume of 20ml. Cycling conditions for
methylated and unmethylated strand of miR-34b/c were as follows:
preheating at 951C for 10min followed by 40 cycles of denaturation
at 951C for 30s, annealing at 591C for 30s and extension at 721C
for 30s, and a final extension at 721C for 7min. For unmethylated
strand of miR-148a: preheating at 951C for 10min followed by 40
Table 1 Primers list for methylation-specific PCR for miR34b/c and miR-148a, base pair and the annealing temperature (Tm) of PCR
Genes Primer sets PCR Tm (1C) Base pair
miR 34b/c, unmethylated Forward: 50-TGGTTTGTGGGGTTTTAAGG-30 59 147
Reverse: 50-TCCCAACCCCAAACCCTA-30
miR 34b/c, methylated Forward: 50-ATTCGTTTCGTTTCGCGTTCGTTTC-30 59 128
Reverse: 50-CTAAAACTAACTCTCTCGACCCCG-30
miR 148a, unmethylated Forward: 50-TTGGTAAAAGTTTAAATAATTATTGA-30 54 115
Reverse: 50-CAACAAAAAAACTACAAAAATCACA-30
miR 148a, methylated Forward: 50-TTGGTAAAAGTTTAAATAATTATCGA-30 56 117
Reverse: 50-CACAACAAAAAAACTACAAAAATCG-30
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and extension at 681C for 30s, and a final extension at 681C for
7min. For methylated strand of miR-148a: preheating at 951C for
10min followed by 40 cycles of denaturation at 951C for 30s,
annealing at 561C for 30s and extension at 721C for 30s, and a final
extension at 721C for 7min. Qiagen’s methylated and unmethy-
lated control DNAs served as a reaction control for PCR.
Preparation of faecal DNA
Faecal DNA was obtained as previously described (Kalimutho et al,
2010b). Faecal DNA of average-risk individuals with no previous
history of colon cancer or polyps (n¼39), CRC patients (n¼28) and
polyps with HGD (n¼12), all provided written informed consent.
DNA from each sample was then subjected to bisulfite conversion
and then whole bisulfitome modification later for MSP. All assays
were carried out in a blind manner by two different technicians.
Whole bisulfitome amplification of bisulfite-converted
faecal DNA
Faecal DNA whole bisulfitome amplification was carried out using
Whole Bisulfitome kit (Qiagen). This assay is based on REPLI-g
technology to allow reproducible and representative amplification
of bisulfite converted genomic (smaller DNA fragment size and
changed nucleotide composition because of the bisulfite conver-
sion), while maintaining the converted sequence representation.
Briefly, bisulphited-converted DNA was added with REPLI-g Midi
DNA Polymerase (Qiagen) and incubated at 281C for 8h. Later
the reaction mixtures were deactivated at 951C for 5min and the
pre-amplified-converted DNA was subjected to 10  dilutions in
ddH2O for MSP reaction.
Statistical analysis
Correlations between methylation status and clinicopathological
features were assessed using v2 or Fisher’s exact probability tests as
appropriate. All P-values presented are two-sided. A P-value o0.05 was
regarded as statistically significant. Survival curves were generated
using Kaplan–Meier method. All statistical tests were performed using
MedCalc (version 9.2.0.1, MedCalc, Mariakerke, Belgium) and SPSS
(version 16.0, SPSS Inc, Somers, NY, USA) software package.
RESULTS
MicroRNAs selection following AZA treatment
To identify which miRNAs undergo specific epigenetic silencing at
50 promoter flanking, we used a super-array RT–qPCR technique
which can simultaneously detect miRNAs that have been silenced
by epigenetic modification. This array consists of 46 miRNAs,
which possessed a CpG island at the promoter region (identified
by http://www.mirbase.org/ and http://www-bimas.cit.nih.gov/
molbio/proscan/ – predicted sequence regions which contain a
significant number and type of transcriptional elements that are
usually associated with Pol II promoter sequences) and with two
endogenous control small RNAs (RNU19 and RNU6B) for data
normalisation. We treated HCT116 and HT29 CRC cell lines with
AZA and found elevated expression of 12 miRNAs (Table 2).
Following this, we determined which miRNAs would have
potential role in the tumour microenvironment. On the basis of
the literature, we found that miR-34b/c was downregulated in most
of cancers including colorectal and have tumour suppressor
properties (He et al, 2005; Chang et al, 2007; Hermeking, 2010). In
addition, miR-148a was correlated to the tumour metastasis which
involved a panel of cancer models (Lujambio et al, 2008). Thus,
based on these previous findings, we chose two miRNAs (miR-34b/c
and miR-148a) for further evaluation using MSP in CRC fresh
frozen and faecal specimens. We avoided selection of certain
miRNAs from our list that were upregulated following AZA
treatment for two reasons; (i) some miRNAs have been reported
previously to be overexpressed in CRC vs matched tissues and
(ii) we particularly looked for screening markers which would
detect cancer more accurately than the available screening markers
and with a high degree of sensitivity.
Expression of miR-34b/c and miR-148a following AZA
treatment
Having determined that miR-34b/c and miR-148a were involved in
cancer progression, we analysed these miRNAs to ensure that what
we observed with super array technique was paralleled with single
RT–qPCR analysis. To assess the effects of miR-34b/c and
miR-148a promoter methylation, four CRC cell lines (HCT116,
HT29, LoVo and HCT15) were further treated with AZA for 5 days.
We found that all CRC cell lines responded concordantly to the
AZA treatment as shown in Figures 1A and B. For miR-34b/c,
about a 6-fold change in expression level was observed followed by
LoVo (3.3-fold), HT29 (3-fold) and HCT15 (2.5-fold; Figure 1A,
upper panel). In contrast, in HT29 cells we found a strong increase
in expression of miR-148a following AZA treatment (5-fold)
followed by HCT15 (3-fold), LoVo (2.6-fold) and HCT116 cell lines
(1.5-fold; Figure 1B, upper panel). These data suggested that the
transcription of these miRNAs (miR-34b/c, miR-148a) were
silenced by hypermethylation modification. The differences in
expression levels of miRNAs following AZA treatment may also
reflect the treatment efficiency. Next, we wanted to confirm
whether the upregulated miR-34b/c and miR-148a expression
Table 2 miRNAs upregulation after the treatment with AZA
hsa-miR HCT116 HT29 Expression in CRC Functions References
1 15b 1.43 2.29 m Cell cycle Xi et al (2006)
2 96 1.58 2.3 m DNA repairs Bandre ´s et al (2006); Sarver et al (2009)
3 99a 3.85 2.23 m Cell inhibition Chen et al (2008)
4 106a 1.23 2.15 km NA Dı ´az et al (2008); Link et al (2010)
5 129 2.6 2.56 k Cell death Bandres et al (2009); Huang et al (2009)
6 135b 1.75 2.02 m DNA repairs Wang et al (2010)
7 146 1.09 2.63 km Anti metastatic Hurst et al (2009); Slattery et al (2011)
8 148a 1.05 3.96 k Methylation Lujambio et al (2008); Chen et al (2010)
9 181c 3.62 1.94 k Oncogenic suppresion Hashimoto et al (2010)
10 219 1.31 3.41 m NA Schetter et al (2008)
11 338 1.85 2.47 NA NA NA
12 34b/c 2.8 3.1 k Cell cycle and apoptosis Toyota et al (2008)
Abbreviations: AZA¼5-aza-20-deoxycytidine; CRC¼colorectal cancer; miRNAs¼microRNAs; NA¼data not available.
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Restoration of miR-34b/c expression was more profound in LoVo
and HT29 cells than HCT116 cells (Figure 1A, lower panel).
In contrast, no methylation of miR-148a in HT29 and HCT15 cells
was noticed, whereas more profound restoration of miR-148a
expression was detected in LoVo than HCT116 cells as decreased
in promoter methylation was detected by MSP (Figure 1B,
lower panel).
Analysis of promoter methylation of miR-34b/c in primary
tumours and matched normal tissues using MSP
First, we assessed the promoter methylation of miR-34b/c by MSP
in 81 neoplastic colonic mucosa and 42 matched normal tissues
(Table 3a, upper panel).
We found that 97.5% (n¼79 out of 81) of neoplastic samples
showed promoter methylation of miR-34b/c (Figures 2A and B). In
contrast, promoter methylation of miR-34b/c was only detected in
14.3% (n¼6/42; Po0.001; Figures 2A and B, Table 4) of matched
normal colonic tissues. No correlation were found for miR-34b/c
methylation pattern with clinicopathological status except for one
significant correlation for pTNM stage, P¼0.0110 (Table 4).
However, this result is conflicting as only two samples were not
positive for stage II cancer.
Promoter methylation of miR-34b/c detection in faeces of
CRC patient
Having confirmed that the expression of miR-34b/c is suppressed
by methylation pattern in a large subset of CRC (97.5%), we
wanted to confirm whether the same methylated pattern could be
detected in faecal specimens. We used previously extracted faecal
DNA for MSP for miR-34b/c methylation detection (Table 3b,
lower panel; Kalimutho et al, 2010b) and used REPLI-g technology
to enhance the detection rate of low abundant methylated alles in
faeces. This assay would pre-amplify the low abundant methylated
copies, which is the main drawback in faecal-DNA methylation
analysis. We found that 75% (n¼21 out of 28) of CRC cases were
positive for promoter methylation of miR-34b/c (Figure 2C, upper
panel, Table 5). At the same time, we analysed colonoscopy faecal
DNA from negative patients and found that only 13% (n¼5 out of
39) of cases had a positive methylation pattern for miR-34b/c.
This result mirrored the data obtained for miR-34b/c in primary
tissue samples (Table 4, Figure 2C, middle panel). Furthermore,
we wanted to confirm whether the same methylated pattern could
be observed in HGD. However, we found that only two cases were
positive for miR-34b/c methylation, n¼12 (Figure 2C, lower panel,
Table 5).
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Figure 1 Methylation status of miR-34b/c and miR-148a in a panel of
CRC cell lines assessed by RT–qPCR and methylation-specific PCR (MSP).
Fold change expression of miR-34b/c (A, upper panel) and miR-148a
(B, upper panel) following 10mM demethylating agent 5-aza-20-deoxycy-
tidine over 5 days of incubation in HCT116, HT29, LoVo and HCT15
assessed by RT-qPCR and by means of a 2
^ DDCq method. Corresponding
methylation-specific PCR for miR-34b/c (A, lower panel) and miR-148a
(B, lower panel) showing the decrease in methylation pattern following
10mM demethylating agent 5-aza-20-deoxycytidine. Lane UM and M
corresponded to unmethylated and methylated reaction respectively.
Qiagen methylated and unmethlated control (ctrl) DNAs served as a
reaction control for PCR. NTC¼negative template control; POS¼posi-
tive template control; AZA¼5-aza-20-deoxycytidine.
Table 3 Demographic of total patients analysed for both tumour and
faecel samples
(A) Total of CRC tissue samples (n) 122
Median age both female and male (range) 68.0 (35–89)
CRC samples
Male 48
Median age (range) 69.5 (42–84)
CRC samples
Female 33
Median age (range) 62(35–89)
Normal colon mucosa samples 41
Male 28
Median age (range) years 68.5 (52–84)
(B) Total of faecal samples (n)7 9
Median age both female and male (range) 62 (28–88)
Male 32
Median age (range) 62 (35–79)
CRC patients 28
Male 13
Median age (range) years 66 (49–79)
High-grade dysplasia 12
Male 8
Median age (range) years 62 (55–74)
CRC/polyp-free subjects 39
Male 11
Median age (range) years 58 (35–65)
Abbreviation: CRC¼colorectal cancer.
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clinicopathological features
Next, we analysed the promoter methylation pattern of miR-148a
on the same tumour samples analysed for miR-34b/c. We also
wanted to correlate miR-148a methylation pattern with clinico-
pathological features. No significant correlation was found
between miR-148a methylation status with clinicopathological
features except for a trend (although not significant) with female
gender (P¼0.08; Table 4), and with advanced age (P¼0.101). We
found that stage III (65%) and stage IV (75%) disease were more
prone to have methylated pattern for miR-148a but this was not
significant. Moreover, pT4 tumours were fully methylated (100%)
compared with pT tumours in which only 65% were positive for
methylation. Overall, 65% of CRC tumour tissues were positive for
miR-148a methylation.
We also wanted to determine the prognostic value of miR-148a
methylation status in this patient cohort. Surgical approach in
patients with colon cancer consisted of standard hemicolectomy
(via laparotomic or laparoscopic approach) with negative macro-
scopic resection margin and regional lymphadenectomy in all
cases. The median number (range) of removed lymph nodes was
17 (3–56). In rectal cancer, laparotomic/laparoscopic low anterior
resection or abdominoperineal resections with total mesorectal
excision were performed; the median number of removed lymph
nodes was 13 (range: 4–37). Overall survival was calculated
according to the Kaplan–Meier method in 60 patients available for
survival analysis, considering cancer related death as the end
point. The median follow-up period was 46 months (range: 1–266
months). Comparison between survival curves was performed with
the log-rank test. The 10-year survival rate of the entire series was
60% (Figure 3A). Survival was significantly related to the stage of
the tumour, and depth of invasion was one of the most important
prognostic factors (log-rank test: Po0.05; Figure 3B). Interest-
ingly, we found a trend towards lower overall survival in the
patients with methylated miR-148a alleles (10-year survival
probability: 48%) compared with patients with unmethylated
miR-148a alleles (10-year survival probability: 65%; Figure 3C);
however, the difference was not statistically significant (log-rank
test: P¼0.561) because of the small number of patients available
for survival analysis.
DISCUSSION
Previous studies have shown that half of the miRNAs are located in
or near CpG islands, which are transcriptionally regulated by DNA
methylation process that varies between normal and tumour cells
(Lujambio et al, 2007, 2008). For example, the methylation pattern
of miR-124a is tumour specific, whereas miR-127 is methylated in
both normal and tumour tissues (Saito et al, 2006; Lujambio et al,
2008), and let-7a-3 is methylated in normal tissues, whereas it
shows a hypomethylation pattern in lung adenocarcinomas
(Brueckener et al, 2007). However, the mechanism underlying
the deregulation of miRNAs in cancer has not yet been fully
elucidated.
With regard to this, we focused our study on the identification
of miRNA with low expression in CRC and which may be involved
in the development of CRC tumourigenesis. We evaluated
expression levels of 46 miRNAs and found that 12 miRNAs were
upregulated following AZA treatment. Of these, we decided to
further investigate two miRNAs, miR-34b/c and miR-148a, which
also previously been reported (Lujambio et al, 2008; Toyota et al,
2008); however, the clinicopathological features have not been fully
evaluated in colorectal tumours. Two other main reasons for
selecting these miRNAs are: (i) first, to evaluate the methylation
pattern of miR-34b/c in tumours tissues in order to extend the
work of Toyata et al (2008) and to further evaluate it in faecal
samples. This would allow us to develop faecal-DNA-based
markers for CRC screening; (ii) second, miR-148a was correlated
to metastasis properties, yet no clinical correlation with methylation
pattern is available for CRC. We also reasoned that miRNAs may be
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Figure 2 Methylation-specific PCR (MSP) reactions for the miR-34b/c and miR-148a promoter region in tumour and faecal specimens derived from CRC
and/or normal individual. (A and B) MSP analysis for miR-34b/c in matched CRC samples. (C) MSP analysis for miR-34b/c in faeces of CRC (upper panel),
colonoscopy negative individuals (middle panel) and high-grade dysplasia (lower pane). (D) MSP analysis for miR-148a in matched CRC tissues. Lane UM
and M corresponded to unmethylated and methylated reaction, respectively. Qiagen methylated and unmethylated control (CTRL) DNAs served as a
reaction control for polymerase chain reaction. NTC¼negative template control; POS¼positive template control; P¼patients; F-P1¼samples derived
from faeces of CRC and normal individuals.
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sa better class of tumour marker because of their broad regulatory
functions and the ability to measure their expression levels with far
better accuracy than is currently achievable for mRNA.
Thus, to further elucidate the role of these miRNAs, four CRC
cell lines were treated with AZA, which allows us to demonstrate
that reduced expression of both miRNAs is directly related to
promoter methylation. The most striking evidence from our study
is that the CpG island of the promoter region of miR-34b/c are
hypermethylated in 97.5% CRC cases, and this methylation is,
therefore believed to be tumour specific for CRC. The high
percentage of methylation pattern in these CRC cases, and the
contribution of miR-34 family on the p53 network, suggest that
miR-34b/c may be involved in the response to colorectal
tumourigenesis. As induction of cell cycle arrest, senescence and
apoptosis are the mechanisms of oncosuppression by miR-34
family (Chang et al, 2007; Hermeking, 2010), permanent inactiva-
tion due to epigenetic silencing may result in a selective advantage
for cancer cell proliferation. The first report by Toyata et al (2008)
on methylation pattern revealed that miR-34b/c was aberrantly
hypermethylated in primary CRC tumours. They showed that
epigenetically silenced miR-34b/c could possibly be involved in the
early process of tumourigenesis. Besides, Corney et al (2010)
recently reported downregulation of miR-34b/c in ovarian cancer.
They found that miR-34b/c is significantly reduced in stage IV
compared with stage III tumours. Accordingly, their data support
our observation in which methylation patterns are inversely
correlated towards tumour stage in CRC. Furthermore, the results
obtained by this study combined with our own observation, could
correlate miR-34b/c hypermethylation status into the development
of screening markers for CRC detection.
We further evaluated miR-34b/c methylation in faecal speci-
mens. Alteration in the genome that would lead to the progression
of cancer could be detected using faecal specimens from CRC
patients. Faecal DNA analysis was shown to represent a novel non-
invasive method for CRC detection (Dong et al, 2001; Kalimutho
et al, 2010b). We found that almost 75% of the CRC patients could
be detected using faecal specimens. This is considered a good
percentage to detect cancer using faeces as a screening marker, as
Table 4 Association of miR-34b/c and miR-148a methylation pattern with clinocopathological features in tumour tissue specimen
Tumour tissue samples
miR-34b/c miR-148a
n Methylated Unmethylated n Methylated Unmethylated
Sex 81 78
Male 48 48 0 46 26 20
Female 33 31 2 32 25 7
P¼0.3181 P¼0.0835
Tumour location 80 78
Proximal colon 15 15 0 15 96
Distal colon and rectum 64 64 2 63 42 21
P¼0.8112 P¼0.8526
pT stage 79 78
T1 2 20 1 10
T2 24 24 2 26 15 11
T3 48 48 0 46 30 16
T4 5 50 5 50
P¼0.2272 P¼0.2774
pTNM stage 81 78
II 15 13 2 15 96
III 57 57 0 54 35 19
IV 9 90 9 72
P¼0.0110* P¼0.6668
Normal colon mucosa/control patients 42 63 6 39 10 29
Po0.0001* P¼1.0000
*P-value indicative significant data produced. The bold values indicate the total number of patients analyzed in this pilot study.
Table 5 Association of miR-34b/c methylation pattern with clinoco-
pathological features in faecal specimen
Faecal samples
miR-34b-c
n¼79 Methylated Unmethylated P-values
Sex 28
Male 13 10 3
Female 15 11 4 P¼0.8268
Tumour location 28
Proximal colon 7 4 3
Distal colon and
rectum
21 17 4 P¼0.497
pTNM stage 28
05 3 2
I2 2 0
II 6 3 3
III 3 2 1
Unknown 9 8 1
Unclassified 1 1 0
a 22 0 P¼0.5055
High-grade dysplasia 12 2 10
Normal colon mucosa/
control patients
39 5 34 Po0.0001*
aHistology report not available, as the patients underwent chemoradiotheraphy or
underwent surgery at a different location. *P-value indicative significant data
produced.
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smethylated faecal DNA is almost inflexible to detect in the complex
microenvironment of faeces. Furthermore, our data are based on a
small group of faecal analysis, thus a large randomised blind study
should take place to evaluate the actual sensitivity of this marker
for CRC screening. In addition, the low percentage of CRC
detection in faeces compared with 98% in tumour samples maybe
because of the nature of the technique used for MSP observation.
Hence, more advanced techniques, such as pyrosequencing or even
quantitative-MSP using a specific probe of minor groove binder,
would enhance the detection rate of miR-34b/c in faeces. However,
as the methylation pattern of miR-34b/c shows almost no trend on
tumour stage and possesses a high level of promoter methylation
state in CRC, both in tumour and feaces, this would facilitate the
feasibility of assaying faecal miR-34b/c as an additional test in
clinical settings.
Next, we wanted to see whether the hypermethylation of
miR-148a could correlate into clinicopathological features of
CRC. The miR-148a expression is shown to be downregulated in
human breast cancer and undifferentiated in gastric cancer
(Lehmann et al, 2008; Katada et al, 2009). DNA methylation-
associated silencing of miR-148 expression is identified in human
cancer cell lines established from lymph node metastasis of colon,
melanoma, and head and neck cancer, suggesting its role in the
development of metastasis (Lujambio et al, 2008). Duursma et al
(2008) have shown that overexpression of miR-148a leads to a
reduction in the expression of de novo DNA-methyl-transferase-3b
(DNMT3b) enzyme. The suppression of miR-148a, in contrast,
induces increased expression of DNMT3b. The evidence shows
that alteration of DNMT3b expression clearly contributes to CRC
tumourigenesis. Lin et al (2006) as well Jin et al (2009) showed
that the increased expression patterns of DNMT3b protein in
Apc
Min/þ increases colorectal carcinogenesis because of the
hypermethylation of tumour suppressors genes. Also, Ahmed
et al (2008) showed that reducing expression of DNMT3b in PC3
tumour cells induces the loss of methylation at the promoters of
several tumour suppressor genes such as APC, RB1 and RER-b.
Therefore, methylation at the promoter of miR-148a leads to
increased expression of DNMT3b, which in turn inactivates its
tumour suppressor function in most of the cancers. The
correlation of our data with miR-148a promoter methylation
pattern, together with Lujambio et al (2008), allows us to link the
epigenetically silenced miR-148a with the progression to advanced
tumour stage. For example, 65% (n¼30 out of 46) of patients with
stage T3, 100% (n¼5) stage T4 and 78% (n¼7 out of 9) with stage
N2 of CRC, have a condition of promoter methylation of miR-148a.
Very recently, Chen et al (2010) reported the downregulation of
miR-148a and miR-152 in gastric and CRC by expression analysis
in which they found a strong correlation between these two
miRNAs. In support of our data, they also reported that no
statistical correlation was found with clinicopathological features
including sex, age, tumour location, histological grade, pN stage or
lymphatic vessel invasion in gastrointestinal cancers. Despite this,
we observed that the positive cases of promoter methylation of
miR-148a have a lower survival rate than the negative cases (48 vs
65% at 10 years). In addition, the number of cases in our patient
cohort is too small to investigate a potential impact of treatment
stratified according to miR-148a methylation status, and this may
represent a clinical limitation of this study. Further prospective
studies may be designed in order to assess the potential clinical
utility of multimodality treatments in tumours with more
aggressive biology, identified by miR-148a expression.
In conclusion, as many CRC patients present with advanced
disease, early detection leads to reduced mortality. Therefore,
developing a miR-34b/c methylation assay as a diagnostic tool for
early detection of CRC would have substantial clinical benefits. On
the other hand, follow-up for the disease progression with targeted
molecular markers such as miR-148a would enable classification of
the prognosis of the disease as well as being a tool for therapy
monitoring in patients having had CRC. Moreover, the reduced
expression of miR-34b/c and miR-148a because of the epigenetic
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Figure 3 Box and Whisker plot and Kaplan–Meier disease-free survival analysis for CRC patients according to miR-148a hypermethylation pattern.
(A) The 10-year survival rate (60%) of CRC patients was calculated using the Kaplan–Meier method. (B) Survival rate of CRC patients according to depth
of invasion. The difference is statistically significant (log-rank test: Po0.05). (C) The prognostic value of miR-148a methylation status was with a trend
towards lower survival rate in patients with methylated alleles (10-year survival probability: 48%) compared with unmethylated cases (10-year survival
probability: 65%), log-rank test: P¼0.561.
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ssilencing could be considered as an important target of
antineoplastic therapy development.
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